Department of Gastrointestinal Oncology, Moffitt Cancer Center, University of South Florida, Tampa, Fla., USA.
Oncology. 2014;87(2):125-32. doi: 10.1159/000361051. Epub 2014 Jul 8.
The development of distant metastases of squamous cell carcinoma of the anal canal (SCCA) is rare but has a poor prognosis. A combination of carboplatin and paclitaxel is commonly used for treating squamous cell cancer in different organs, but its efficacy in advanced SCCA is unclear. The objective of this study is to determine the tolerability and outcome of patients with advanced SCCA on carboplatin plus paclitaxel treatment at the Moffitt Cancer Center.
Retrospective analysis was conducted by looking at records from the Moffitt Cancer Center Tumor Registry from January 2007 to January 2012. Eligible patients had to have a diagnosis of SCCA and have received carboplatin plus paclitaxel every 3 weeks as part of the treatment plan.
Eighteen patients fulfilled the criteria; 14 were initially diagnosed with early-stage disease and received concurrent chemoradiation, but then relapsed. Median age was 56 years. Upon diagnosis of metastatic disease, 12 patients received carboplatin plus paclitaxel as a first-line treatment. Five patients had received prior systemic chemotherapy regimens and 1 had received prior local regional therapy. The response rate was high at 53% including 3 patients who achieved a complete response. Median overall survival was 12.19 months.
Carboplatin and paclitaxel treatment shows encouraging activity in advanced SCCA.
肛门鳞状细胞癌（SCCA）远处转移的发展较为罕见，但预后较差。卡铂联合紫杉醇联合治疗常用于治疗不同器官的鳞状细胞癌，但在晚期肛门鳞状细胞癌中的疗效尚不清楚。本研究的目的是确定在莫菲特癌症中心接受卡铂联合紫杉醇治疗的晚期肛门鳞状细胞癌患者的耐受性和结局。
通过回顾莫菲特癌症中心肿瘤登记处 2007 年 1 月至 2012 年 1 月的记录进行回顾性分析。合格的患者必须诊断为 SCCA，并接受每 3 周一次的卡铂联合紫杉醇治疗，作为治疗计划的一部分。
18 名患者符合标准；14 名患者最初被诊断为早期疾病并接受同期放化疗，但随后复发。中位年龄为 56 岁。在转移性疾病诊断时，12 名患者接受卡铂联合紫杉醇作为一线治疗。5 名患者曾接受过系统化疗方案，1 名患者曾接受过局部区域治疗。客观缓解率为 53%，包括 3 名完全缓解的患者。中位总生存期为 12.19 个月。
卡铂和紫杉醇治疗在晚期肛门鳞状细胞癌中显示出令人鼓舞的疗效。
